The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages 1-11

  Vitagliano, Donata ^a   De Falco, Valentina ^a   Tamburrino, Anna ^a   Coluzzi, Sabrina ^a   Troncone, Giancarlo ^a   Chiappetta, Gennaro ^b   Ciardiello, Fortunato ^c   Tortora, Giampaolo ^a   Fagin, James A ^d   Ryan, Anderson J ^e   Carlomagno, Francesca ^a   Santoro, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN RET; PROTEIN SHC; THREONINE; TRYPTOPHAN; VANDETANIB;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MUTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79251531655     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0292     Document Type: Article

References (41)

1. van Amerongen R & Berns A 2008 Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape. Cancer Cell 13 5-7. (doi:10.1016/j.ccr.2007.12.019)
2. Asai N, Jijiwa M, Enomoto A, Kawai K, Maeda K, Ichiahara M, Murakumo Y & Takahashi M 2006 RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease. Pathology International 56 164-172. (doi:10.1111/j.1440-1827.2006.01942.x)
3. Baselga J 2006 Targeting tyrosine kinases in cancer: the second wave. Science 312 1175-1178. (doi:10.1126/science.1125951)
4. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R et al. 2008 Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clinical Cancer Research 14 5069-5080. (doi:10.1158/1078-0432.CCR-07-4905)
5. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, Colantuoni V & Fusco A 1995 Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochemical and Biophysical Research Communications 207 1022-1028. (doi:10.1006/bbrc.1995.1287)
6. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002a ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62 7284-7290.
7. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A & Santoro M 2002b The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Research 62 1077-1082. (Pubitemid 34160290)
8. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 6056-6063. (doi:10.1038/sj.onc.1207810)
9. Ciardiello F & Tortora G 2008 EGFR antagonists in cancer treatment. New England Journal of Medicine 358 1160-1174. (doi:10.1056/NEJMra0707704)
10. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR et al. 2003 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clinical Cancer Research 9 1546-1556.
11. Cooley LD, Elder FF, Knuth A & Gagel RF 1995 Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genetics and Cytogenetics 80 138-149. (doi:10.1016/0165-4608(94) 00185-E)
12. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA & Fagin JA 2008 RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research 68 4183-4191. (doi:10.1158/0008-5472.CAN-08-0413)
13. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG & Kerbel RS 2009 Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 232-239. (doi:10.1016/j.ccr. 2009.01.021)
14. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F et al. 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. Journal of Clinical Endocrinology and Metabolism 93 682-687. (doi:10.1210/jc.2007-1714)
15. Fagin JA, Tuttle RM & Pfister DG 2010 Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 95 2621-2624. (doi:10.1210/jc.2010-0800)
16. Hayden EC 2009 Cutting off cancer's supply lines. Nature 458 686-687. (doi:10.1038/458686b)
17. Herbst RS, Heymach JV, O'Reilly MS, Onn A & Ryan AJ 2007 Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs 16 239-249. (doi:10.1517/13543784.16.2.239) (Pubitemid 46206638)
18. Huang SC, Torres-Cruz J, Pack SD, Koch CA, Vortmeyer AO, Mannan P, Lubensky IA, Gagel RF & Zhuang Z 2003 Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 88 459-463. (doi:10.1210/jc.2002-021254)
19. Johanson V, Ahlman H, Bernhardt P, Jansson S, Kölby L, Persson F, Stenman G, Swärd C, Wängberg B, Stridsberg M et al. 2007 A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocrine-Related Cancer 14 433-444. (doi:10.1677/ERC-06-0033)
20. Knight ZA, Lin H & Shokat KM 2010 Targeting the cancer kinome through polypharmacology. Nature Reviews. Cancer 10 130-137. (doi:10.1038/nrc2787)
21. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF & McDonald NQ 2006 Structure and chemical inhibition of the RET tyrosine kinase domain. Journal of Biological Chemistry 281 33577-33587. (doi:10.1074/jbc.M605604200)
22. van der Laan BF, Freeman JL & Asa SL 1995 Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5 67-73. (doi:10.1089/thy.1995.5.67)
23. Leong SS, Zeigel R, Chu TM, Baylin S & Mirand EA 1981 A new cell line for study of human medullary thyroid carcinoma. In Advances in Thyroid Neoplasia, pp 95-108. Ed. M Andreoli. Rome: Field Educational Italia.
24. Loges S, Mazzone M, Hohensinner P & Carmeliet P 2009 Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15 167-170. (doi:10.1016/j.ccr.2009.02.007)
25. Michieli P 2009 Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle 8 3291-3296. (doi:10.4161/cc.8.20.9741)
26. Nilsson O, Wangberg B, Kolby L, Schultz GS & Ahlman H 1995 Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. International Journal of Cancer 60 645-651. (doi:10.1002/ijc. 2910600514)
27. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D & Casanovas O 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 220-231. (doi:10.1016/j.ccr.2009.01.027)
28. Robinson BG, Paz-Ares L, Krebs A, Vasselli J & Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 95 2664-2671. (doi:10.1210/jc.2009-2461)
29. Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, Leskela S, Leandro-Garcia L, Lopez-Jimenez E, Leton R et al. 2010 Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocrine-Related Cancer 17 7-16. (doi:10.1677/ERC-08-0304)
30. Santoro M & Carlomagno F 2006 Drug insight: smallmolecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology & Metabolism 2 42-52. (doi:10.1038/ncpendmet0073)
31. Schlumberger M, Carlomagno F, Baudin E, Bidart JM & Santoro M 2008 New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice. Endocrinology & Metabolism 4 22-32. (doi:10.1038/ncpendmet0717)
32. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 94 1493-1499. (doi:10.1210/jc.2008-0923)
33. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK & Wells SA Jr 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New England Journal of Medicine 353 1105-1113. (doi:10.1056/NEJMoa043999) (Pubitemid 41317433)
34. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C et al. 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 287-290. (doi:10.1126/science.1142946)
35. de la Torre NG, Buley I, Wass JA & Turner HE 2006 Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocrine-Related Cancer 13 931-944. (doi:10.1677/erc.1.01210)
36. Tortora G, Ciardiello F & Gasparini G 2008 Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clinical Practice. Oncology 5 521-530. (doi:10.1038/ncponc1161)
37. Vidal M, Wells S, Ryan A & Cagan R 2005 ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Research 65 3538-3541. (doi:10.1158/0008-5472.CAN-04-4561)
38. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL et al. 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research 62 4645-4655.
39. Wells SA Jr & Santoro M 2009 Targeting the RET pathway in thyroid cancer. Clinical Cancer Research 15 7119-7123. (doi:10.1158/1078-0432.CCR-08- 2742)
40. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Vasselli JR, Read J & Schlumberger M 2010 Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). Journal of Clinical Oncology 28 15s (suppl; abstract 5503). (doi:10.1200/JCO.2009.23.6604)
41. Yarden Y 2001 The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. European Journal of Cancer 37 S3-S8. (doi:10. 1016/S0959-8049(01)00230-1)